Chaperone

Personalized Medicines Platform

An AI-enhanced SaaS solution for cell and gene therapy

Background:
Cell and Gene Therapies (CGT) are personalized treatments utilizing living cells from a patient or donor to create the "drug"



Common CGT treatments:
Regenerative gene therapy
Immunotherapy (CAR T-Cell against cancer)
Stem cell therapy – autologous
Stem cell therapy – allogenic

Industry challenges:
According to FDA the primary challenges for CGT manufacturers are not within the clinical portion of a drug approval, as patients are treated with their own cells and not a synthesized chemical.
It is rather the product manufacturing and quality control processes that cause problems.



Caused by:
1. A complex supply chain
2. Fragmented system landscape
3. Complex compliance requirements



Solution architecture and overview:



Project opportunities:
1. A generative AI-model for creating compliance documents
2. A clinic/hospital front-end with a cloud data model and GDPR hash service
3. A manufacturer back-end with a cloud data model
4. A logistics front-end with interfaces and a CoC AI-agent
5. A sample label system based on the ZPL protocol
6. A mobile application

Relevant skills/interests:
- Microsoft Azure Cloud native applications
- Microsoft Azure AI studio (OpenAI and ML)
- Relational databases (SQL)
- Generative AI
- Life sciences and compliance

Collaborators:
- Microsoft Denmark
- Microsoft for startups
- DTU
- DTU Skylab
- Life science academy for startups

Chaperone

Contact: Arild Bernth Jakobsen (arild@chaperone.dk)/+45 30240374 or Karl Heuer (karheu@dtu.dk)